Erasca Executives Face Securities Lawsuit Over Misleading Trial Data

The legal action centers on a period between January 14, 2025, and April 26, 2026. According to the complaint, the company’s share price plummeted 53.9%—a loss of $11.59 per share—following revelations of patent infringement allegations and a patient death during clinical trials. Plaintiffs argue that Lim and Chacko, who signed Sarbanes-Oxley certifications for annual reports, either knew or recklessly disregarded that preclinical comparisons to rival drug RMC-6236 were fundamentally flawed.

Under Section 20(a) of the Securities Exchange Act, the lawsuit seeks to hold these executives personally accountable for their oversight of public disclosures. The filing contends that the defendants used these allegedly inflated statements to maintain stock prices, facilitating a major capital raise that closed in early 2026. Joseph E. Levi, the attorney representing the class, emphasized that the integrity of executive certifications remains the core issue for shareholders seeking to recoup their losses.